 | Webcast
Gilead Sciences at Bank of America Merrill Lynch Health Care Conference (Live)
05/16/12 at 3:40 p.m. PT |
 |
|
| Date | Title | | | 05/11/12 | FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV |  | | 05/10/12 | FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV | | | 05/08/12 | Gilead Sciences to Present at the Bank of America Merrill Lynch 2012
Health Care Conference on Wednesday, May 16 | | | 05/01/12 | Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the
Treatment of Chronic Lymphocytic Leukemia | | | 05/01/12 | Gilead Sciences to Present at the Deutsche Bank 37th
Annual Health Care Conference on Tuesday, May 8 | | | 04/26/12 | Gilead Sciences Announces First Quarter 2012 Financial Results | | | 04/19/12 | Gilead Announces Sustained Virologic Response Data for 12-Week
Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1
Hepatitis C Patients | | | 04/19/12 | Gilead Announces Early Sustained Virologic Response Rates for GS-7977
Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients | | | 04/19/12 | Gilead Sciences to Release First Quarter 2012 Financial Results on
Thursday, April 26, 2012 | | | 04/18/12 | Gilead Sciences to Present New Hepatitis B and C Data at European
Conference on Liver Disease This Week | | | 03/08/12 | Data Show Gilead’s Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study | | | 03/07/12 | Gilead’s Quad Single Tablet Regimen for HIV Non-Inferior to Atripla® in Pivotal Phase 3 Study | | | 03/06/12 | Gilead Sciences Quad Study 102 Results Conference Call on Wednesday, March 7, 2012 | | | 03/06/12 | Gilead Sciences to Present at the Barclays Capital 2012 Global Healthcare Conference on Tuesday, March 13 | | | 02/29/12 | Gilead Sciences to Present at the Cowen & Company 32nd Annual Health Care Conference on Wednesday, March 7 | | | 02/24/12 | Gilead Sciences to Present at Two Upcoming Investor Conferences | | | 02/17/12 | Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study | | | 02/13/12 | U.S. FDA Grants Priority Review for Truvada® for Reducing the Risk of Acquiring HIV Infection | | | 02/02/12 | Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial Results | | | 01/26/12 | Gilead Sciences to Release Fourth Quarter and Year End 2011 Financial Results on Thursday, February 2, 2012 | | | 01/24/12 | Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV | | | 01/18/12 | U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV | | | 01/18/12 | Roy D. Baynes, MD, PhD, to Join Gilead Sciences as Senior Vice President, Oncology Therapeutics | | | 01/17/12 | Gilead Sciences Completes Acquisition of Pharmasset, Inc. | | | 01/12/12 | Gilead Sciences Completes Tender Offer for All Outstanding Shares of Pharmasset, Inc. | | | 01/06/12 | Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period | | | 01/05/12 | Gilead Sciences to Present at the 30th Annual JPMorgan Healthcare Conference on Monday, January 9 | |
|
|
The information in these news pages should not be deemed accurate or current except as of the date of the particular press release or posting. Gilead has no intention of updating and specifically disclaims any duty to update the information in the press releases. The press releases may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. | 
